Baricitinib

🧮 Dose calculator

Rheumatoid arthritis · Regimen source: FDA Olumiant · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Olumiant · 8.1

  “Risk Summary Based on the findings from animal reproduction studies, OLUMIANT may cause fetal harm during pregnancy.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Olumiant · 8.2

  “Because of the potential for serious adverse reactions in nursing infants advise women not to breastfeed during treatment with OLUMIANT and for 4 days after the last dose (approximately 5 to 6 elimination half-lives).”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Olumiant · 8.4

  “The safety and effectiveness of OLUMIANT for the treatment of severe alopecia areata have been established in pediatric patients 12 years of age and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Olumiant · 8.5

  “Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration ( 2.6 )] .”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Olumiant · 8.3

  “Contraception Based on animal studies, OLUMIANT may cause fetal harm when administered during pregnancy [see Use in Specific Populations ( 8.1 )] .”